Novo Nordisk

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 54,400 people in 80 countries and markets its products in around 170 countries. For more information visit novonordisk.com.

Our US Research & Development hub, located in the Greater Boston area, brings together the best talent to drive life science innovation. Located in Lexington, Watertown and Cambridge, our teams reflect the full scope of R&D, from early research through late-stage clinical development. We are building for the future by creating a distinct R&D community based on collaboration, partnerships, and cutting-edge research across multiple modalities and therapeutic areas. We recognize that improving human health starts here and that patients rely on us. By combining the speed and agility of biotech with the quality, resources, and stability of a large pharmaceutical company, our US R&D hub will benefit from the best of both worlds to develop new medicines that meet the needs of patients.

Novo Nordisk is its people. We rely on the diversity of perspectives from colleagues all around the world. Our forward thinking, supported by careers that are as dynamic as we are, makes Novo Nordisk a great place to be and be from. This is your moment. Here we don’t stand still, we never give up – we make an impact. We’re trusted to have the courage. Together, we make it happen.

  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
75 Hayden Avenue
Lexington, MA 02421
  • Featured Employer
NEWS
The analysis showed a 52-week glucose remission rate of 65.2% among the 69 patients being followed.
The massive genetic data mining project aims to gain deeper insight into how human genetic variants affect risk for common complex diseases.
Novo Nordisk will take over Prothena’s wholly-owned subsidiary and gain full global intellectual property rights and other related rights for the latter’s ATTR amyloidosis business and pipeline.
It was another busy week for clinical trial news ahead of the July 4 holiday in the U.S. Here’s a look.
Three partnerships were signed today between biopharmaceutical and therapeutics companies in a bid to develop treatment for major diseases with high mortality rates.
Eli Lilly and Novo Nordisk published their data in The Lancet Diabetes & Endocrinology and presented them at the ADA conference.
This program limits the prices drug manufacturers can charge for therapies sold to specific healthcare facilities, including public hospitals and community health centers.
Seattle-based clinical-stage biopharmaceutical company Lumen Bioscience is teaming up with Novo Nordisk to explore research and development opportunities within obesity, among other metabolic disorders.
FDA
Wegovy is the first and only once-weekly GLP-1 receptor agonist that’s been approved for weight control in people living with obesity. This is the same drug used to treat type 2 diabetes.
JOBS
IN THE PRESS